TW403656B - Pharmaceutical anti-tnf antibodies compositions comprising for the treatment of disorders with an elevated serum level of interleukin-6 - Google Patents
Pharmaceutical anti-tnf antibodies compositions comprising for the treatment of disorders with an elevated serum level of interleukin-6 Download PDFInfo
- Publication number
- TW403656B TW403656B TW084100744A TW84100744A TW403656B TW 403656 B TW403656 B TW 403656B TW 084100744 A TW084100744 A TW 084100744A TW 84100744 A TW84100744 A TW 84100744A TW 403656 B TW403656 B TW 403656B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- thf
- interleukin
- composition according
- serum content
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
重要的角色。 此點最後導致臨床上研究使用抗-THF抗II治療敗血病患 者。 在最近公開之多中心II期研究中,使用老鼠單株抗 -TNF抗體治療嚴重敗血病,然而已發現,以抗體治療後之 存活率而言,餺族群(80位患者 > 並未受益。由存活櫬率 來看,似乎僅血液循環中TNF濃度提高之患者,因接受高 劑董抗-THF抗體投藥而受益(C. J.費雪(Fisher)等人 * 加護験學(Critical Care Medicine),第 21卷,No. 3,ρ· 318-327, 1993)。此外,此實驗中並探討血漿中 ΤΝΡ與I 1-6含量之相闞性。 细胞素間白素-6(1卜6)於敗血病中所扮演的角色並不 明瞭且眾說紛云。有些敗血病患者發現血清中1丨-6含量增 加(哈克(Hack)等人,Blood L1 (1989), 1704-1710) Ο 經濟部中央標準局員工消費合作社印製 (.請先閲讀背面之注意事項再填寫本頁) 華格(Waage)曾說明细胞素11-6及11-8濃度與休克嚴重 性之相醑性,但不論其單獨或與TNF組合,就死亡率而言 *對休克徵候之發展卻沒有影響(華格之”腫痼壊死因子 ”,B.包德勒钃韉,紐約拉文出版社,1992年,P. 275-283 (Waage in "Tuior Mecrosis Factors", ed. B. Beutler, Raven Press, New York, 1992, p. 275 -283 ) 〇 有些科學家認為11-6對敗血性休克具有有利之影響•因 為丨丨-6依負踴饋授制作用抑制LPS所誘發之TNF生產(李 本紙張尺度適用中國國家梯準(CNS ) A4規格(210X297公釐) 403656 at _B7____ 五、發明説明(4) - 本發明係有鼷抗THF抗體於治療血清間白素-6含量增加 之病症上之用途。 已知腫瘤壞死因子(THF) —詞包括二種细胞毒性因子( TNF-α與TNF-/8) ·此等因子主要由活化之淋巴球及軍核 细胞產生。 EP 260 610曾揭示例如:抗-TNF抗體,據稱可用於與血 中THF濃度提高有醑之病變,如:敗血性休克、排斥移植 物、過敏、自嫌免疫疾病、休克肺、凝血陣礙、或發炎性 册骼疾病•使TNF不活化。 患者《內之Μ血清間白素含量增加為特性之病症實例為 移植後遺症、自體免疫疾病及特定言之某些種類之敗血病 Ο 敢血病在翳學教科害中之定義為细菌性病原菌自病竃開 始進入血流中,誘發許多主觀及客観病理症狀之路床通稱 名飼。此外尚發現•臨床病症可能»病原菌種類、身體之 反應性、原發之病《及所涉及器官之變化等廣泛地變化( 史都等人,”内科醫學",第13版,第570頁,司圖加特市 谷斯塔费雪出版社* 1984年(Stur· et al·., "Grundbegriffe der Inneren Medizin" 13th edition, page 570, Gustav Fischer Verlag, Stuttgart, 1984) 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) )° 許多種细胞素曾被認為涉及敗血病之複雜病理生理病變 。根據勖物寊驗數據(包特勒(Beutler)等人,Science (1985) 869-871) * TNF特別在敗血性休克中扮演重 本紙張尺度適用中阈囤家標準(CNS ) A4規格(210X 297公釐)
重要的角色。 此點最後導致臨床上研究使用抗-THF抗II治療敗血病患 者。 在最近公開之多中心II期研究中,使用老鼠單株抗 -TNF抗體治療嚴重敗血病,然而已發現,以抗體治療後之 存活率而言,餺族群(80位患者 > 並未受益。由存活櫬率 來看,似乎僅血液循環中TNF濃度提高之患者,因接受高 劑董抗-THF抗體投藥而受益(C. J.費雪(Fisher)等人 * 加護験學(Critical Care Medicine),第 21卷,No. 3,ρ· 318-327, 1993)。此外,此實驗中並探討血漿中 ΤΝΡ與I 1-6含量之相闞性。 细胞素間白素-6(1卜6)於敗血病中所扮演的角色並不 明瞭且眾說紛云。有些敗血病患者發現血清中1丨-6含量增 加(哈克(Hack)等人,Blood L1 (1989), 1704-1710) Ο 經濟部中央標準局員工消費合作社印製 (.請先閲讀背面之注意事項再填寫本頁) 華格(Waage)曾說明细胞素11-6及11-8濃度與休克嚴重 性之相醑性,但不論其單獨或與TNF組合,就死亡率而言 *對休克徵候之發展卻沒有影響(華格之”腫痼壊死因子 ”,B.包德勒钃韉,紐約拉文出版社,1992年,P. 275-283 (Waage in "Tuior Mecrosis Factors", ed. B. Beutler, Raven Press, New York, 1992, p. 275 -283 ) 〇 有些科學家認為11-6對敗血性休克具有有利之影響•因 為丨丨-6依負踴饋授制作用抑制LPS所誘發之TNF生產(李 本紙張尺度適用中國國家梯準(CNS ) A4規格(210X297公釐) 五、發明説明(3 A7 B7 桕特(Libert)等人· ”腫瘸壊死因子:分子與细胞生物 學及睡床相«性",W.菲爾钂梅,巴塞市卡格出版社· 1 9 9 3 年,p . 1 2 6 -1 31 (L i b e r t e t a 1 . i n " T u in 〇 r* Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance", ed. W. Fiers, Kapgep, Basel, 1993, p. 126-131 ) 〇 吾等現已驚人地發現,THF拮抗繭特別成功地用為治療 Μ血清間白素-6含ft增加為特性之病症之藥物。 根據本發明使用THF拮抗劑治療敗血病特別成功•例如 :當治療之初11-6含量為500微微克/ .毫升之敗血病患者 接受治療時,其死亡率顬著下降。而血清11-6含最离於 1000撖微克/亳升之患者接受根據本發明治療後•受益情 形特別佳。 血清11-6平均含量至少比健康者之生理血淸含量增加 10倍。 已發現敗血病患者之血淸II-6濃度至高可達健摩者含量 之 20,000倍。 "正常” 11-6血淸含ft通常低於檢拥限值•可能醣所採 用之分析条统稍有差異。然而其最高值為20微撖克/奄升 請 先 閲 讀 背 之 注
I 裝 訂 Λ 經濟部中央標準局負工消費合作社印裝 血清11-6滬度可利用一般檢拥法如:RIΑ或ELISA拥定 。一種極合適之檢测系統為由美奇尼斯公司(Medgenix) 供應之 I 1-6-EASIA。 II-6濃度亦可利用活性分析法測定♦其中例如:分析 本紙張尺度適用中闽國家橾华(CNS ) A4規格(210X 297公釐) 4036^6 A7 B7 五、發明説明(4 ·) - C-反應性蛋白質。 (請先閲讀背面之注意事項再填寫本頁) 合逋之TNF拮抗劑為抗-TNF抗Μ,TNF受體及其可溶性 片段· TNF结合蛋白質或彼等可與THF受體結合但無TNF 活性之THF衍生物。此等THF括抗劑之特性為可捕捉已形 成之THF ,且不會使之接觸到THF受體或與TNF競爭受體 〇 然而·可防止THF形成或釋出之TNF拮抗劑亦瑭合根據 本發明之用途。此等物霣抑制例如:TNF基因表現或由前 體型釋出THF 。 這種TNF-拮抗劑活性已說明於例如:黄瞟呤素衍生物、 糖皮質激素、前列胨素Ε2、沙利寶 (thalidoiide)、閬 白素-4、間白素-10 、粒性細胞一剌激性因子(G-CSF)、 環孢素及<x -抗胰蛋白_。因此*此類化合物亦*合作為 TNF拮抗劑。 抗-TNF抗》特別逋用於根據本發明。 逋用於根據本發明之抗-THF抗髓係巳知者(EP 260 610 • EP 351 789,EP 218 868)。可使用多株及單株抗體。 此外,THF-结合性抗體片段如:Fab或F(ab’)2片段或單 鍵Fv片段亦逋用。 經濟部中央榡準局員工消費合作社印製 此外•人類化或人類抗-THF抗體或其TNF-结合性片段亦 極逋合•因為此等分子不會使人類患者出現任何抗小白鼠 抗原性。 亦可使用各種不同抗-TNF抗體之混合物或抗-TNF抗體與 TNF受體片段之混合物作為活性物質。 —7 — 本紙張尺度適用中國囤家標準(CNS ) A4規格(210X 297公釐) 403656_;2_ 五、發明説明(5 ·) - 本發明包括轚藥姐合物,其中除了無毒性、惰性、《藥 上合逋之載體外,尚包括抗-TNF抗賭•及此等姐合物之生 產方法。 抗-TNF抗髓係依生物技術上生產活性物質常用之方法調 配*通常配成液«調配物或冷凍乾燥物(參見例如:哈格 氏製藥手冊(Hagers Handbuch der pharBazeutischen Praxis),第2 卷,第5 版,1991年 * p. 720, ISBH 3-540-52459-2 )。上述»藥姐合物係依習知方法生產· 例如:由(一種或多種)活性物質與(一種或多種)載劑 混合。 經濟部中央標準扃員工消費合作杜印製 (請先閱讀背面之注意事項再填寫本頁) 通常*已證實埋用於根據本發明之(一種或多種)活性 物質之有利投藥總最為每24小時約0.1至約1000 ·最好 0.1至10奄克/公斤,若遘當時* Μ分成數次分開劑簷或 連績灌流形式投式•且若遘當時,持鑛數天之治療期· Κ 達到最嫌结果。投藥方式可為經靜脈內短暫地灌流單一劑 置或Μ—天劑量持績長時間灌流24小時。單一爾量最好包 含約0.1至約10«克/公斤«重之(一種或多種)活性物 質。然而,必g時可傾離上述劑量,端賴待治療之患者之 年龄與體型及基本病變之性質與嚴重性、姐合物型態與蕖 物投與塱態、及投第持續時間與間隔等而定。下列實例進 一步說明本發明。 g例 Μ老鼠抗-TNF抗«片段(F(abM2)治療敗血病患者 於多中心豳床研究中•使用各種不同劑量之抗-THF抗體 —8 — 木纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央橾準局負工消费合作杜印製 403656 $ 五、發明説明(6、) .. 片段或安慰劑治療一共122位敗血病患者。 所進行之四種翳療法相異處僅在於單一劑量抗-THF抗體 片段之含量不同。其係0.1奄克/公斤鱷里,〇.3毫克/ 公斤腰重或1.0奄克/公斤體簠。第四姐患者接受》假療 法”(安慰劑)供對照用。患者係隨機分配成使用抗 -THF抗雅片段之四種療法之一。上述療法除了敗血病患者 之標準療法外,於診斷後(=符合實驗欏準者),每間隔 8小時投與短暫灌流共9次(即進行3天)。此實驗共有 122位患者參與,3 4位分配在0.1奄克/公斤劑量姐· 30位分配在0.3奄克/公斤劑悬姐· 29位在1 .〇毫克/公 斤繭量姐,及29位為安慰劑姐。 療法開始之前· 122位中有119位患者可测得I丨-6血濟 濃度。36位之11-6血清濃度>1000微微克/ ¾升,83位 <1000微微克/亳升。 ^ ·1Α出示各種不同處理姐(安慰劑,0.1 ,0.3及1.0 毫克抗體/公斤體里)中* 1丨-6>1000撖撖克/毫升之族 群之死亡率。 圖1Β出示各種不同處理姐(安慰劑,0.1 ,0.3及1.0
毫克抗體/公斤體重)中· 11-6<1000微微克/奄升之族 群之死亡率。J 11-6> 1000微微克/奄升之患者中*當以抗-TKF抗«片 段治療時,死亡率會《劑董增加而下降,由80.0Χ (安慰 劑姐)降至36.U ( 1.0奄克/公斤抗體)(’圔1Α)。 II-6<1000嫌微克/亳升之患者中* Μ抗-THF抗體片段 —9 — 本紙張尺度適用中國國家懔準(CNS ) Α4規格(210X297公釐) --------.—裝------訂------Λ (請先閲讀背面之注意事項再填寫本頁) 403656 A7 B7 五、 發明説明(-7 治療時並不會降低死亡率,反之卻稍提高(安慰劑姐 30.455 ·相對地1.0 «克/公斤之抗體姐則為38.9X)(匿 1B) 〇 此睡床實驗结果清楚地證實僅當敗血病患者之血淸 11-6>1000微微克/毫升含量時,方可使用抗-THF抗體成 功地治療嚴重之敗血病;而對血淸11-6微微克/奄升含量 之患者之治療劑不成功,且有時候甚至出現反效果。 ----------彳裝-- (請先閲讀背面之注意事項再填寫本頁) 訂 1 經濟部中央樣準局員工消費合作社印¾ 本紙张尺度適州中國國家標準(CNS ) A4規格(2丨OX297公釐)
Claims (1)
- A8 B8 C8 D8 - 第84100744^專利由謫案 a. :r S 40;决〇5^气和丨範潭I修正本(85年3月) 申貪專利範圍 公告木 3 . 4 > «Νέ療,特徴為間白素-6血濟含量垄少高於健康自願 告索ί|ί血清含量10倍以上病症之Β藥組合物,其包含 :.τνΜ抗劑。 申猜專利範圍第1項之》槩組合物 -6血清含量係500撤微克/¾升或更多。 根據申請專利範園第1項之B蕖組合物 -6血清含量係10 00微微克/«升或更多。 根據申請專利範園第1至3項中任一項之醫蕖組合物 其中THF拮抗劑係單株抗體。 根據申請專利範圔第1至3項中任一項之醫蕖組合物 其中THF拮抗覿係人類或人類化抗體。 其中間白素 其中間白素 . 裝 I 订 ~~ I-~:咏.>.- (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消費合作社印裝 i張 -紙 本 標 家 國 國 中一用 適 I釐 公 A8 B8 C8 D8 - 第84100744^專利由謫案 a. :r S 40;决〇5^气和丨範潭I修正本(85年3月) 申貪專利範圍 公告木 3 . 4 > «Νέ療,特徴為間白素-6血濟含量垄少高於健康自願 告索ί|ί血清含量10倍以上病症之Β藥組合物,其包含 :.τνΜ抗劑。 申猜專利範圍第1項之》槩組合物 -6血清含量係500撤微克/¾升或更多。 根據申請專利範園第1項之B蕖組合物 -6血清含量係10 00微微克/«升或更多。 根據申請專利範園第1至3項中任一項之醫蕖組合物 其中THF拮抗劑係單株抗體。 根據申請專利範圔第1至3項中任一項之醫蕖組合物 其中THF拮抗覿係人類或人類化抗體。 其中間白素 其中間白素 . 裝 I 订 ~~ I-~:咏.>.- (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消費合作社印裝 i張 -紙 本 標 家 國 國 中一用 適 I釐 公
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4403669 | 1994-02-07 | ||
DE4409513A DE4409513C1 (de) | 1994-02-07 | 1994-03-19 | Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel |
Publications (1)
Publication Number | Publication Date |
---|---|
TW403656B true TW403656B (en) | 2000-09-01 |
Family
ID=25933592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW084100744A TW403656B (en) | 1994-02-07 | 1995-01-27 | Pharmaceutical anti-tnf antibodies compositions comprising for the treatment of disorders with an elevated serum level of interleukin-6 |
Country Status (20)
Country | Link |
---|---|
US (2) | US6235281B1 (zh) |
EP (1) | EP0804236B1 (zh) |
JP (1) | JPH09509411A (zh) |
CN (1) | CN1140414A (zh) |
AT (1) | ATE235917T1 (zh) |
AU (1) | AU1520195A (zh) |
BR (1) | BR9506741A (zh) |
CA (1) | CA2182723A1 (zh) |
CZ (1) | CZ290843B6 (zh) |
DK (1) | DK0804236T3 (zh) |
ES (1) | ES2197912T3 (zh) |
FI (1) | FI963101A0 (zh) |
HR (1) | HRP950052B1 (zh) |
HU (1) | HU220995B1 (zh) |
IL (1) | IL112427A (zh) |
NO (1) | NO963280L (zh) |
NZ (1) | NZ278607A (zh) |
PT (1) | PT804236E (zh) |
TW (1) | TW403656B (zh) |
WO (1) | WO1995020978A1 (zh) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DE19746868A1 (de) * | 1997-10-23 | 1999-04-29 | Knoll Ag | Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen |
US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
CA2876779A1 (en) * | 2000-05-12 | 2001-11-22 | Genzyme Corporation | Modulators of tnf-.alpha. signaling |
RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
BR0206160A (pt) * | 2001-05-25 | 2004-10-26 | Abbott Gmbh & Co Kg | Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos |
CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US7925894B2 (en) * | 2001-07-25 | 2011-04-12 | Seagate Technology Llc | System and method for delivering versatile security, digital rights management, and privacy services |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
US7860806B2 (en) * | 2002-03-12 | 2010-12-28 | Nokia Corporation | System and method for charging for data reception |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20040018197A1 (en) * | 2002-04-26 | 2004-01-29 | Promega Corporation | Treatment for weight loss |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
MY169308A (en) * | 2002-07-19 | 2019-03-21 | Abbvie Biotechnology Ltd | Treatment of tnf? related disorders |
UA76639C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
WO2004047826A1 (en) * | 2002-11-21 | 2004-06-10 | Genzyme Corporation | Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
JP4928079B2 (ja) * | 2002-11-21 | 2012-05-09 | ジェンザイム・コーポレーション | 慢性組織移植片拒絶を阻害するためのジアミド誘導体の使用 |
ATE472556T1 (de) * | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
US7435799B2 (en) * | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
WO2006125229A2 (en) | 2005-05-16 | 2006-11-23 | Abbott Biotechnology Ltd. | Use of tnf inhibitor for treatment of erosive polyarthritis |
JP4846799B2 (ja) * | 2005-07-05 | 2011-12-28 | バイオテンプト ベー.フェー. | 腫瘍の治療 |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
SG10201406358SA (en) | 2006-04-05 | 2014-12-30 | Abbvie Biotechnology Ltd | Antibody purification |
WO2007120656A2 (en) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
US9624295B2 (en) | 2006-04-10 | 2017-04-18 | Abbvie Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
PT2120991E (pt) * | 2007-02-12 | 2014-05-02 | Biotempt Bv | Tratamento d a hemorragia traumática com oligopéptidos curtos |
EP2162469A4 (en) * | 2007-05-21 | 2012-08-01 | Alderbio Holdings Llc | NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES |
US8404235B2 (en) * | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
KR101615715B1 (ko) * | 2007-05-21 | 2016-04-27 | 앨더바이오 홀딩스 엘엘씨 | Il-6에 대한 항체 및 이의 용도 |
US8252286B2 (en) * | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
JP5934652B2 (ja) | 2009-11-24 | 2016-06-15 | アルダーバイオ ホールディングス エルエルシー | Il−6に対する抗体およびその使用 |
FR2962651A1 (fr) | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections fonctionnelles du tractus gastro-intestinal |
FR2962656A1 (fr) | 2010-07-15 | 2012-01-20 | Oleg Iliich Epshtein | Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps |
EP2643016A2 (en) | 2010-11-23 | 2013-10-02 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of anemia |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
CN104955480A (zh) | 2013-01-25 | 2015-09-30 | 西蒙有限公司 | 用于选择性减少循环的生物活性可溶性tnf的组合物以及用于治疗tnf介导的疾病的方法 |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2016160976A2 (en) | 2015-03-30 | 2016-10-06 | Abbvie Inc. | Monovalent tnf binding proteins |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
JOP20190162A1 (ar) | 2016-12-30 | 2019-06-27 | Biocad Joint Stock Co | تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5183657A (en) * | 1988-03-11 | 1993-02-02 | Celltech Limited | Antibodies for use in antilymphocyte antibody therapy |
WO1990000902A1 (en) * | 1988-07-18 | 1990-02-08 | Chiron Corporation | Monoclonal antibodies reactive with cachectin |
AU630497B2 (en) * | 1989-09-05 | 1992-10-29 | Immunex Corporation | Tumor necrosis factor-alpha and -beta receptors |
DE07012625T1 (de) * | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
IL99120A0 (en) * | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
EP0605522B1 (en) * | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
-
1994
- 1994-03-19 NZ NZ278607A patent/NZ278607A/en unknown
-
1995
- 1995-01-24 IL IL11242795A patent/IL112427A/en not_active IP Right Cessation
- 1995-01-27 US US08/687,328 patent/US6235281B1/en not_active Expired - Fee Related
- 1995-01-27 JP JP7520363A patent/JPH09509411A/ja not_active Abandoned
- 1995-01-27 WO PCT/EP1995/000291 patent/WO1995020978A1/de active IP Right Grant
- 1995-01-27 CN CN95191517A patent/CN1140414A/zh active Pending
- 1995-01-27 BR BR9506741A patent/BR9506741A/pt not_active Application Discontinuation
- 1995-01-27 EP EP95906353A patent/EP0804236B1/de not_active Revoked
- 1995-01-27 DK DK95906353T patent/DK0804236T3/da active
- 1995-01-27 AU AU15201/95A patent/AU1520195A/en not_active Abandoned
- 1995-01-27 CZ CZ19962322A patent/CZ290843B6/cs not_active IP Right Cessation
- 1995-01-27 HU HU9602169A patent/HU220995B1/hu not_active IP Right Cessation
- 1995-01-27 TW TW084100744A patent/TW403656B/zh not_active IP Right Cessation
- 1995-01-27 CA CA002182723A patent/CA2182723A1/en not_active Abandoned
- 1995-01-27 ES ES95906353T patent/ES2197912T3/es not_active Expired - Lifetime
- 1995-01-27 PT PT95906353T patent/PT804236E/pt unknown
- 1995-01-27 AT AT95906353T patent/ATE235917T1/de not_active IP Right Cessation
- 1995-02-06 HR HRP4409513.9A patent/HRP950052B1/xx not_active IP Right Cessation
-
1996
- 1996-08-06 FI FI963101A patent/FI963101A0/fi not_active IP Right Cessation
- 1996-08-06 NO NO963280A patent/NO963280L/no not_active Application Discontinuation
-
2001
- 2001-02-14 US US09/782,290 patent/US20010010819A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1995020978A1 (de) | 1995-08-10 |
FI963101A (fi) | 1996-08-06 |
NO963280L (no) | 1996-10-04 |
ATE235917T1 (de) | 2003-04-15 |
ES2197912T3 (es) | 2004-01-16 |
CZ232296A3 (en) | 1997-03-12 |
NO963280D0 (no) | 1996-08-06 |
PT804236E (pt) | 2003-08-29 |
HRP950052A2 (en) | 1997-10-31 |
IL112427A (en) | 1998-12-06 |
BR9506741A (pt) | 1997-10-21 |
AU1520195A (en) | 1995-08-21 |
CN1140414A (zh) | 1997-01-15 |
EP0804236B1 (de) | 2003-04-02 |
FI963101A0 (fi) | 1996-08-06 |
CZ290843B6 (cs) | 2002-10-16 |
HU220995B1 (hu) | 2002-07-29 |
US6235281B1 (en) | 2001-05-22 |
JPH09509411A (ja) | 1997-09-22 |
DK0804236T3 (da) | 2003-07-21 |
CA2182723A1 (en) | 1995-08-10 |
HU9602169D0 (en) | 1996-10-28 |
NZ278607A (en) | 1999-05-28 |
HUT76875A (en) | 1997-12-29 |
EP0804236A1 (de) | 1997-11-05 |
HRP950052B1 (en) | 2000-04-30 |
US20010010819A1 (en) | 2001-08-02 |
IL112427A0 (en) | 1995-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW403656B (en) | Pharmaceutical anti-tnf antibodies compositions comprising for the treatment of disorders with an elevated serum level of interleukin-6 | |
Ruth et al. | CXCL16‐mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway | |
Tian et al. | Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor | |
Martiney et al. | Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent | |
Vecchiarelli et al. | Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. | |
US20030012786A1 (en) | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients | |
Burns et al. | Production of interleukin-8 (IL-8) by cultured endothelial cells in response to Borrelia burgdorferi occurs independently of secreted [corrected] IL-1 and tumor necrosis factor alpha and is required for subsequent transendothelial migration of neutrophils | |
Schwartzkopff et al. | CXC chemokine ligand 4 (CXCL4) down-regulates CC chemokine receptor expression on human monocytes | |
JP2012526846A (ja) | ループス治療のための方法および組成物 | |
Håkansson et al. | Migratory responses of eosinophil and neutrophil granulocytes from patients with asthma | |
Fujimoto et al. | Eosinophil activation in patients with pulmonary fibrosis | |
Moon et al. | Brown adipose tissue ameliorates autoimmune arthritis via inhibition of Th17 cells | |
Lendvai et al. | Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice | |
Hoyer et al. | The effect of 6-mercaptopurine on delayed hypersensitivity in guinea pigs | |
AU756167B2 (en) | Application of TNF antagonists as medicaments for treating septic diseases | |
de Bie et al. | Effect of interleukin-16-blocking peptide on parameters of allergic asthma in a murine model | |
Plotnikoff | Drug resistance due to inbreeding | |
Uehara et al. | Churg-Strauss syndrome presenting as myositis following unaccustomed exercise | |
DE69533804T2 (de) | Mimetika von aus alternden Zellen abgeleiteten Hemmern der DNA-Synthese | |
Erger et al. | Tumor Necrosis Factor α Is Necessary for Granulocyte-Macrophage-Colony-Stimulating-Factor-Induced Eosinophil Transendothelial Migration | |
KR100414505B1 (ko) | 높은혈청수준의인터류킨-6을갖는질환을치료하기위한약물로서의항-tnf항체의용도 | |
Kotiw et al. | Detection of anti‐TNFα activity in canine hyperimmune serum using a TNFα inhibition assay | |
AU5394001A (en) | The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
Hong et al. | Level-Specific Differences in Systemic Expression of | |
AU1549599A (en) | The use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of the interleukin-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |